Trials explorer

AI-generated summary

- The ZANGEA trial tests zanidatamab together with pembrolizumab and chemotherapy in adults with metastatic gastroesophageal adenocarcinoma that is HER2-positive and PD-L1-positive, and who have not had palliative treatment before. - It is an open-label, single-arm phase II study enrolling about 80 patients at roughly 30 sites in Germany and Austria to assess efficacy, safety, tolerability, and quality of life. - The study also includes exploratory aims to compare results with a historical regimen and to identify molecular biomarkers that predict response or toxicity. - Key exclusions include untreated CNS metastases, active autoimmune disease, prior anti-HER2 therapy for GEA, certain infections, and pregnancy or breastfeeding.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma is being studied. Conditions: Glioblastoma • Eligibility: Phase 2 Inclusion Criteria: 1. Age ≥ 18 years. 2. Able to understand and provide a signed informed consent that fulfills the relevant IRB or IEC guidelines. 3.…. Goal: This study consists of 2 portions. The phase 2 portion is an open-label, single-arm study to evaluate the safety and efficacy of NAI, PD-L1 t-haNK, and bevacizumab combination therapy in participants with recurrent or progressive GBM. Phase/Status/Sponsor: Unknown phase; RECRUITING; ImmunityBio, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC is being studied. Conditions: TNBC - Triple-Negative Breast Cancer, PD-L1 Positive • Eligibility: Inclusion Criteria: 1. Female patients with breast cancer aged \>= 18 years. 2. Based on the pathological report of the latest biopsy or other pathological specimens, the histology…. Goal: This study is aimed to evaluate the efficacy and safety of Sacituzumab Tirumotecan combined with Toripalimab for first-line treatment of PD-L1 positive unresectable Locally Advanced/metastatic triple negative breast cancer (a/mTNBC). Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Tianjin Medical University Cancer Institute and Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Sintilimab Combined With Chemotherapy for Adjuvant Treatment of Mucosal Melanoma After Surgery is being studied. Conditions: Mucosal Melanoma, PD-L1 Positive • Eligibility: Inclusion Criteria: 1. Sign a written informed consent form (Informed Consent, ICF) and be able to comply with the visit schedule and related procedures outlined in the protocol.…. Goal: Melanoma has emerged as the fastest-growing malignancy in recent years, with incidence and mortality rates among both men and women in East Asian countries exceeding the Asian average. China ranks fifth among East Asian nations in melanoma incidence. Phase/Status/Sponsor: Unknown phase; RECRUITING; The First Hospital of Jilin University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

HC010 in First-line PD-L1 Positive Advanced NSCLC Patients is being studied. Conditions: NSCLC • Eligibility: Inclusion Criteria: * 1\. Voluntarily participate in the study, communicate well with investigators, understand and voluntarily complete the study process according to this protocol, and sign the informed…. Goal: Phase 2 clinical study to evaluate the efficacy, safety, pharmacokinetics and immunogenicity profile of HC010 for injection in patients with positive PD-L1 (TPS ≥1%) Phase/Status/Sponsor: Unknown phase; RECRUITING; HC Biopharma Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests ABSK043, an oral PD-L1 inhibitor, in people with unresectable or metastatic angiogenic sarcomas, specifically intimal sarcoma, head and neck angiosarcoma, or epithelioid hemangioendothelioma. It aims to see if ABSK043 helps these cancers, to evaluate its safety and tolerability, and to identify biomarkers in tumor tissue or blood that could predict response or side effects. About 20 participants are planned to take part at the Princess Margaret Cancer Centre. Key exclusions include active autoimmune disease requiring systemic therapy, prior PD-1/PD-L1 therapy, active brain metastases, HIV or active hepatitis, pregnancy, active infections, and recent cancer treatments or other investigational drugs.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The trial tests an off-the-shelf, multi-peptide liver cancer vaccine (IMA970A) given with Montanide and the PD-L1 blocker Durvalumab. It is a single-arm, open-label Phase I study in adults with very early to intermediate stage hepatocellular carcinoma who have completed standard treatments and have no active disease. The study aims to assess safety, tolerability, and immune response to this combination and to see if it can reduce recurrence or progression. Eligibility includes adults over 18 with specific HLA types (HLA-A*02 or HLA-A*24), adequate organ function, and good performance status; key exclusions include recent systemic cancer treatment, liver transplantation, active autoimmune disease, prior anti-PD-1/PD-L1/CTLA-4 therapy with certain toxicities, and other high-risk conditions.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study is being studied. Conditions: Pancreatic Cancer, PD-L1, PD-1 Inhibitor +2 • Eligibility: Inclusion Criteria: * Age ≥ 18 years, regardless of gender; * ECOG score of 0 to 1; * Patients with histologically or cytologically confirmed pancreatic malignancy; * No…. Goal: To investigate the activating effect of local lesion low-dose radiotherapy (2Gy) on the tumor immune microenvironment, and the efficacy, safety, and feasibility of its combination with pembrolizumab and standard therapy in patients with advanced pancreatic cancer. Concurrently, to preliminarily establish an efficacy prediction model for the early identification of patient populations who would benefit from the treatment, thereby providing a theoretical foundation for the implementation of precision medicine. Phase/Status/Sponsor: Unknown phase; RECRUITING; Zhejiang Provincial People's Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The study tests whether people with advanced solid tumors who have stable disease can stop PD-1/PD-L1 treatment after one year without harming outcomes. It is for patients being treated with PD-1/PD-L1 drugs (like pembrolizumab, nivolumab, atezolizumab, durvalumab, or avelumab). Participants are randomly assigned to stop treatment after about one year or continue treatment until the cancer progresses, to learn the best length of therapy. To join, patients must have at least stable disease on scans within six weeks of randomization; those with progressive disease before randomization or immune-related toxicity that prevents staying on therapy beyond one year are excluded.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer is being studied. Conditions: Advanced Lung Cancer • Eligibility: Inclusion Criteria: * Aged ≥18 years at the time of giving informed consent. * Histological or cytological confirmed unresectable advanced/metastatic lung cancer. Histological classification may be based on…. Goal: This study aims to investigate the combination of BNT324, a B7-H3 antibody-drug conjugate (ADC) with BNT327, a programmed death-ligand 1 (PD-L1) and vascular endothelial growth factor (VEGF) bispecific antibody, in participants with advanced/metastatic or relapsed/progressive small cell lung cancer (SCLC) and non small cell lung cancer (NSCLC). Phase/Status/Sponsor: Unknown phase; RECRUITING; BioNTech SE.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) is being studied. Conditions: Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer +27 • Eligibility: Inclusion Criteria: * At least 18 years of age or 12 to 17 years of age after Safety Review Committee approval. * Locally advanced or metastatic solid malignancy…. Goal: The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, tolerability and preliminary efficacy of multiple dose levels of rezatapopt as monotherapy and in Phase 1b in combination with pembrolizumab. Phase/Status/Sponsor: Unknown phase; RECRUITING; PMV Pharmaceuticals, Inc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests Puxi-Sam (puxitatug samrotecan) as a single-drug treatment versus doctors’ choice of chemotherapy (doxorubicin or paclitaxel) for people with B7-H4–selected advanced or metastatic endometrial cancer that has progressed after platinum-based therapy and anti-PD-1/PD-L1 therapy. It is a phase III, randomized, multicenter global study enrolling about 700 participants in a 1:1 ratio. The study aims to find out if Puxi-Sam can help people live longer without their cancer getting worse or live longer overall, and how it affects safety and quality of life. Key exclusions include uterine sarcomas or neuroendocrine carcinoma, prior TOP1 inhibitor therapy or Puxi-Sam/B7-H4 therapies, active or a history of ILD/pneumonitis or autoimmune disorders, and more than 12 months since completing platinum therapy in the curative setting without additional platinum.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial compares rilvegostomig plus gemcitabine and cisplatin versus durvalumab plus gemcitabine and cisplatin as first-line treatment for advanced biliary tract cancer. - It is for adults with unresectable locally advanced or metastatic BTC, including intrahepatic or extra-hepatic cholangiocarcinoma and gallbladder cancer, who have not yet received systemic therapy for advanced disease and have measurable disease with good performance status. - The study aims to learn which regimen provides better efficacy and acceptable safety when used at the start of treatment. - Key exclusions include ampullary cancer, prior systemic therapy for unresectable or metastatic BTC, prior exposure to immune-targeting therapies, active autoimmune disease requiring steroids, and certain interstitial lung disease or serious skin conditions. - Sponsor: AstraZeneca; Status: Recruiting; Phase: Unknown.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66) is being studied. Conditions: Colorectal Neoplasms • Eligibility: The main inclusion and exclusion criteria include but are not limited to the following: Inclusion Criteria: Inclusion Criteria include, but are not limited to: * Has a histologically…. Goal: In this study, Chinese participants with MSI-H or dMMR advanced colorectal cancer will be assigned to receive either pembrolizumab or the Investigator's choice of 1 of 6 standard of care (SOC) chemotherapy regimens for treatment. There is no hypothesis testing for this study. Phase/Status/Sponsor: Unknown phase; RECRUITING; Merck Sharp & Dohme LLC.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing is being studied. Conditions: Locally Advanced Alveolar Soft Part Sarcoma, Metastatic Alveolar Soft Part Sarcoma, Locally Advanced Non Small Cell Lung Cancer +7 • Eligibility: * INCLUSION CRITERIA: * Participants with a locally advanced or metastatic pathologically confirmed cancer whose NCI Licensed Independent Practitioner (LIP) determined they are candidates for treatment with atezolizumab,…. Goal: Background: A type of drug called monoclonal antibody immune checkpoint inhibitors are often used in cancer treatment. These drugs help the body s immune system fight cancer by blocking proteins that cause cancer cells to grow. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body is being studied. Conditions: Melanoma, Clear-Cell Renal-Cell Carcinoma (ccRCC), Advanced Solid Tumors • Eligibility: Key Inclusion Criteria: Dose escalation cohorts: 1. Histologically or cytologically confirmed diagnosis of solid malignancy (locally advanced or metastatic) with confirmed progression on standard-of-care therapy 2. Participants are…. Goal: This study is researching an experimental drug called REGN10597 alone or in combination with another drug called cemiplimab (called "study drug(s)"). The study is focused on patients with certain solid tumors that are in an advanced stage. Phase/Status/Sponsor: Unknown phase; RECRUITING; Regeneron Pharmaceuticals.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Combined AlloStim+Anti-PD-L1 in 4L MSS Metastatic Colorectal Cancer is being studied. Conditions: Metastatic Colorectal Cancer • Eligibility: Inclusion Criteria: 1. Adult male and female subjects aged 18-80 years at screening visit 2. Pathologically confirmed diagnosis of MSS/pMMR colorectal adenocarcinoma 3. Presenting with metastatic disease: *…. Goal: Experimental immunotherapy in chemotherapy-refractory and immunotherapy-refractory metastatic colorectal cancer patients that have progressed, or are intolerant to, Longsurf (TAS-102) +/- Avastin (bevacizumab) or Stivarga (regorafenib) or Fruzaqla (fruquintinib) combining experimental AlloStim with an anti-programmed death ligand 1 (PD-L1) checkpoint inhibitor drug. Phase/Status/Sponsor: Unknown phase; WITHDRAWN; Mirror Biologics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive is being studied. Conditions: Advanced Solid Tumor • Eligibility: Inclusion Criteria: * Immunotherapy naive and without access to approved and/or available immune checkpoint inhibitor (ICI) therapy. * Measurable disease per RECIST v1.1. * One of the following…. Goal: This study is being conducted to determine the safety, tolerability, and preliminary efficacy of INCB099280 in participants with advanced solid tumors. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Incyte Corporation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer is being studied. Conditions: Extensive-stage Small-cell Lung Cancer • Eligibility: Inclusion Criteria: * Have histologically or cytologically confirmed ES-SCLC (using the AJCC \[American Joint Committee on Cancer\] tumor node metastasis staging system combined with Veterans Administration Lung Study…. Goal: This is a Phase III, multisite, randomized, double-blinded study to investigate pumitamig (BNT327) combined with chemotherapy (etoposide/carboplatin) compared to atezolizumab combined with chemotherapy (etoposide/carboplatin) for the treatment of participants with previously untreated extensive-stage small-cell lung cancer (ES-SCLC). Phase/Status/Sponsor: Unknown phase; RECRUITING; BioNTech SE.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

PD-1 Antibody Plus GEMOX as Postoperative Adjuvant Therapy in Perihilar Cholangiocarcinoma is being studied. Conditions: Perihilar Cholangiocarcinoma • Eligibility: Inclusion Criteria: 1. The patient must sign an informed consent form; 2. Age 18-75 years old, both male and female; 3. ECOG performance status score (PS score) 0…. Goal: This is an open-label,single center,non-randomized,single arm exploratory study. The objective of this study is to evaluate the efficacy and safety of PD-1 antibody plus GEMOX as postoperative adjuvant therapy in perihilar cholangiocarcinoma with positively metastatic lymph nodes. Phase/Status/Sponsor: Unknown phase; RECRUITING; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This phase II randomized trial tests whether giving a PD-1 inhibitor with chemotherapy (gemcitabine–cisplatin) followed by re-irradiation helps people with locally advanced recurrent nasopharyngeal cancer. - It compares immediate re-irradiation after chemo-immunotherapy with a strategy of selective (only certain patients) re-irradiation. - Eligible participants are adults ages 18–70 with local recurrence more than a year after initial treatment, not a candidate for surgery, who achieved complete or partial response after 4–6 cycles of chemo plus PD-1 inhibitor, and have good performance status. - Key exclusions include prior treatment for recurrent NPC or prior PD-1/PD-L1 inhibitors, active autoimmune disease requiring systemic therapy, infections such as HIV/HBV/HCV, interstitial lung disease or significant cardiovascular disease, pregnancy, or other factors that could interfere with participation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Clinical Trial Testing the Safety of BNT327 (an Investigational Drug) and How Well it Works in Patients With Recurrent Glioblastoma is being studied. Conditions: Recurrent Glioblastoma • Eligibility: Inclusion Criteria: * Adults, 18-75 years of age at the time of giving informed consent. Local laws will be followed if the age at consent is older. *…. Goal: This multi-site Phase II study will enroll adults with histologically confirmed diagnosis of World Health Organization (WHO) Grade IV glioblastoma (GBM) consistent with WHO central nervous system (CNS) 2021 criteria who have received prior first-line treatment including with at least radiotherapy and temozolomide, with a Karnofsky performance status (KPS) ≥60, adequate organ function, and at least one measurable lesion according to the response assessment in neuro-oncology (RANO) 2.0 criteria. Phase/Status/Sponsor: Unknown phase; RECRUITING; BioNTech SE.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests nanvuranlat in adults with biliary tract cancer to find a recommended dose regimen (Part A) and to study its effect on overall survival compared with the physician’s best choice (Part B). Participants are 18 years or older with advanced, metastatic, or unresectable BTC who have received one prior platinum-based therapy. Treatments are given every two weeks with safety checks, tumor imaging, and exploratory tests to understand how the drug works. Key exclusions include active CNS metastases, significant cardiovascular disease, HIV not on therapy, active HBV or HCV infection, and pregnancy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine M9241 in Localized High- and Intermediate-Risk Prostate Cancer Treated With Androgen Deprivation Therapy is being studied. Conditions: Cancer Of Prostate • Eligibility: * INCLUSION CRITERIA: * Participants must have histologically or cytologically confirmed localized intermediate or high risk prostate cancer: * Intermediate risk - Gleason 7 disease, PSA less than…. Goal: Background: Prostate cancer is often treated with radiation and ADT (ADT is androgen deprivation therapy). Up to 30% of these cancers recur within 5 years of treatment. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests whether adding durvalumab to the chemotherapy drugs gemcitabine and cisplatin given before surgery helps treat high-risk, resectable intrahepatic cholangiocarcinoma (liver cancer). - It is for adults who are considered candidates for curative surgery. - Researchers want to learn how many patients can complete the pre-surgery therapy and then have the tumor completely removed, as well as rates of major tumor response and overall survival after treatment. - Key exclusions include pregnancy, active autoimmune diseases, active infections (including hepatitis B or C), recent major surgery or current immunosuppressive therapy, and other conditions that could affect safety or results.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The trial tests whether adding pembrolizumab, an immunotherapy drug, to the usual platinum-based chemotherapy after surgery helps people with certain stages of non-small cell lung cancer live longer without the cancer returning. - It is for adults who have had complete surgical removal of stage IIA-IIIB NSCLC (T3-4N2) and who have not received prior systemic treatment for this cancer. - The study compares two timing strategies: pembrolizumab after chemotherapy versus pembrolizumab given at the same time as chemotherapy, to see which approach improves disease-free and overall survival and how it affects side effects and quality of life. - Key eligibility notes include no active autoimmune disease requiring systemic therapy in the past 2 years, no active infection or pneumonitis, not pregnant, and adequate organ function; people with controlled HIV may participate under certain conditions.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma is being studied. Conditions: Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma +6 • Eligibility: Inclusion Criteria: * Patients with measurable or non-measurable (detectable) recurrent endometrial cancer * Measurable disease will be defined and monitored by RECIST v 1.1. Measurable disease is defined…. Goal: This phase II trial tests whether the combination of nivolumab and ipilimumab is better than nivolumab alone to shrink tumors in patients with deficient mismatch repair system (dMMR) endometrial carcinoma that has come back after a period of time during which the cancer could not be detected (recurrent). Deoxyribonucleic acid (DNA) mismatch repair (MMR) is a system for recognizing and repairing damaged DNA. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors is being studied. Conditions: Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer +6 • Eligibility: Inclusion Criteria: 1. Adult participants must be 18 years of age or older 2. Advanced or metastatic solid tumors excluding primary central nervous system (CNS) tumors 3. For…. Goal: The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161 as a single agent and in combination with pembrolizumab. Phase/Status/Sponsor: Unknown phase; RECRUITING; IDEAYA Biosciences.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests the safety and potential benefit of giving pembrolizumab (an immunotherapy) with preoperative radiation and intraoperative radiation therapy (IORT) before and during salvage surgery for persistent or recurrent head and neck squamous cell carcinoma that can be removed surgically. It has three arms comparing different timing and doses of radiation around the surgery, all with pembrolizumab around the operation. Researchers will look at toxicity, locoregional tumor control, progression-free survival, and possible biomarkers (like PD-L1, TNF-alpha, NF-kB, tumor mutational burden) plus quality of life. Eligible participants are adults with resectable persistent or recurrent head and neck cancer, but key exclusions include prior immune checkpoint therapy, active autoimmune disease, HIV/HBV/HCV infection, unresectable disease, distant metastases, pregnancy, or breastfeeding.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This is a first-in-human study testing VVD-130037 in people with advanced solid tumors, using dose escalation and dose expansion, as a single agent or in combination with docetaxel, paclitaxel, or pembrolizumab. - The trial aims to determine safe and tolerable doses and learn how the drug behaves in the body, while gathering early signals about efficacy. - Eligible participants are adults with metastatic or unresectable solid tumors that progressed after standard therapies, with measurable disease and a good performance status (ECOG 0–1); Part 2 adds specific squamous cancers (e.g., sqNSCLC with or without NRF2/CUL3 mutations, HNSCC, ESCC) with prior platinum therapy and/or immune therapy as applicable. - Key exclusions include certain KEAP1 mutations that are not expected to benefit VVD-130037, unresolved toxicity, seizure risk or CNS metastases, uncontrolled hypertension, significant heart problems, prior severe immunotherapy toxicity, and active pneumonitis or ILD.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations is being studied. Conditions: Non Small Cell Lung Carcinoma • Eligibility: Inclusion Criteria: * Must have histologically documented non-squamous (NSq) non small cell lung carcinoma (NSCLC) that is locally advanced or metastatic will be enrolled into the study. *…. Goal: Non small cell lung carcinoma (NSCLC) is the most frequently occurring histologic subtype of lung cancer and is the leading cause of cancer-related deaths worldwide. The purpose of this study is to assess adverse events and change in disease activity when Telisotuzumab Adizutecan (ABBV-400) is given in combination with a programmed cell death receptor 1 (PD1) immune checkpoint inhibitor to adult participants to treat NSCLC. Phase/Status/Sponsor: Unknown phase; RECRUITING; AbbVie.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer is being studied. Conditions: Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma • Eligibility: Inclusion Criteria: * Participant is considered an adult according to local regulation at the time of signing the informed consent form (ICF). * Female participant is not pregnant,…. Goal: Claudin 18.2 protein, or CLDN18.2 is a protein found on cells in the digestive system. It is also found on some tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; Astellas Pharma Global Development, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests a total neoadjuvant therapy plan that starts with induction immunochemotherapy and is followed by chemoradiotherapy before surgery for locally advanced esophageal squamous cell carcinoma. It is for adults aged 18 to 75 with intrathoracic ESCC, good performance status (ECOG 0–1), and adequate organ function whose disease meets locally advanced criteria. The study aims to learn whether this approach improves systemic control, downstages the tumor, and reduces recurrence and metastasis after surgery. Key exclusions include adenocarcinoma, prior thoracic irradiation or chemotherapy, prior anti-PD-1/PD-L1 therapy, active autoimmune disease or infections, HIV, active hepatitis B or C, pregnancy, and other major medical conditions.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies is being studied. Conditions: Gastric Cancer, Esophageal Adenocarcinoma, Hepatocellular Carcinoma +1 • Eligibility: Inclusion Criteria: 1. Age ≥ 18 years 2. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1 3. Histologically confirmed diagnosis of any of the following: • Gastric or…. Goal: The investigators propose to evaluate the safety of drug combinations in patients with advanced gastroesophageal cancer and other gastrointestinal (GI) malignancies. Finding effective novel therapies for patients with advanced gastric cancer and other GI malignancies is an area of great unmet need. Phase/Status/Sponsor: Unknown phase; RECRUITING; Anwaar Saeed.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma is being studied. Conditions: Melanoma (Skin Cancer), Unresectable Melanoma, Metastatic Melanoma • Eligibility: Inclusion Criteria: * Participant has a histologically or pathologically confirmed diagnosis of Stage IIIC, IIID, or IV unresectable or metastatic melanoma. * The participant has an ECOG performance…. Goal: This is a Phase 2, multicenter, open-label study of lifileucel (tumor-infiltrating lymphocytes \[TIL\]) in participants with previously treated advanced melanoma Phase/Status/Sponsor: Unknown phase; RECRUITING; Iovance Biotherapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Melanoma is being studied. Conditions: Melanoma Metastatic, Uveal Melanoma, Metastatic, Mucosal Melanoma • Eligibility: Inclusion Criteria: * Able to provide written informed consent * \[68Ga\]Ga-A9T-3202 uptake in at least one measurable lesion (per RECIST v1.1) on PET scan * Histologically or cytologically…. Goal: The goal of this trial is to see if this investigational drug is safe for adult patients with melanoma that has spread to other parts of the body or cannot be removed by surgery. It will also see if this investigational drug can shrink melanoma tumors in the body. Phase/Status/Sponsor: Unknown phase; RECRUITING; Alpha-9 Oncology USA Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests PULSAR together with dual immune checkpoint inhibitors (PD-1 and CTLA-4 antibodies) and gemcitabine/cisplatin (GC) chemotherapy in people with locally advanced or metastatic cholangiocarcinoma. - It is for adults aged 18 to 75 who have at least one measurable tumor and can receive radiotherapy, immunotherapy, and chemotherapy. - The study aims to determine how well the combination works and how safe it is, and to learn about its effects on the tumor environment and the body's immune response. - Key exclusions include prior anti-PD-1/PD-L1 therapy, active autoimmune diseases (with some exceptions), active infections or HIV/HCV, and having previously received systemic therapy for cholangiocarcinoma. - The trial is currently recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests a three‑drug combo—Apatinib, Adebrelimab, and GEMOX chemotherapy—for adults with unresectable intrahepatic cholangiocarcinoma (ICC). It aims to see if this regimen can achieve more tumor shrinkage and longer survival, while keeping an eye on safety, compared with historical data for chemotherapy alone. Eligible participants are adults 18–75 with confirmed ICC that cannot be removed by surgery or has progressed after prior treatment, and who have good liver function and performance status. Up to 38 people will be enrolled at multiple hospitals; key exclusions include prior immune checkpoint inhibitor treatment, having another active cancer, and conditions like significant ascites or uncontrolled medical issues.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests adding lenvatinib to nivolumab plus chemotherapy for gastric cancer with peritoneal metastasis and malignant ascites. - It is for adults with newly diagnosed or recurrent/metastatic gastric or GEJ adenocarcinoma who have peritoneal metastasis with grade ≥2 ascites and a PD-L1 CPS ≥5. - The study aims to learn about the safety and efficacy of this combination and whether it can improve outcomes, such as survival, in this group. - Key exclusions include uncontrolled illness or infection, pregnancy or breastfeeding, HIV or active hepatitis B/C infection, recent major surgery, and other concurrent cancer therapies.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) is being studied. Conditions: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung • Eligibility: Inclusion Criteria: * Has pathologically (histologically or cytologically) confirmed diagnosis of NSCLC * Has Stage IIIA, IIIB, or IIIC NSCLC by American Joint Committee on Cancer Version 8…. Goal: The purpose of this study is to assess the efficacy and safety of pembrolizumab in combination with concurrent chemoradiation therapy followed by either pembrolizumab with olaparib placebo (Arm 1) or with olaparib (Arm 2) compared to concurrent chemoradiation therapy followed by durvalumab (Arm 3) in participants with unresectable, locally advanced NSCLC. Arms 1 and 2 will be studied in a double-blind design and Arm 3 will be open-label. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Merck Sharp & Dohme LLC.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement is being studied. Conditions: Intrahepatic Cholangiocarcinoma, FGFR2 Gene Rearrangement, FGFR2 Gene Mutation • Eligibility: Inclusion Criteria: 1. Written informed consent and HIPAA authorization for release of personal health information prior to registration. NOTE: HIPAA authorization may be included in the informed consent…. Goal: This is a single arm phase II study of pemigatinib and durvalumab combination in patients with FGFR-2 fusion or rearrangement positive intrahepatic cholangiocarcinoma. Each cycle will be 3 weeks. Phase/Status/Sponsor: Unknown phase; RECRUITING; Mehmet Akce.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) is being studied. Conditions: Triple-Negative Breast Cancer • Eligibility: Inclusion Criteria: * Has centrally confirmed TNBC, as defined by the most recent American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines * Has no evidence of…. Goal: This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TPC) in participants with triple-negative breast cancer (TNBC) who received neoadjuvant therapy and did not achieve a pathological complete response (pCR) at surgery. The primary objective is to compare sacituzumab tirumotecan plus pembrolizumab to TPC (pembrolizumab or pembrolizumab plus capecitabine) with respect to invasive disease-free survival (iDFS) per investigator assessment. Phase/Status/Sponsor: Unknown phase; RECRUITING; Merck Sharp & Dohme LLC.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This multicenter, open-label, single-group trial tests photodynamic therapy using Cosiporfin Sodium together with gemcitabine and cisplatin (GC) for people with locally advanced or recurrent metastatic extrahepatic cholangiocarcinoma that cannot be operated on. - It aims to preliminarily measure efficacy, focusing on the 6-month overall survival rate, and to assess safety and tolerability of the PDT plus GC treatment in patients with biliary obstruction. - Eligible participants are adults with histologically confirmed disease, inoperable or unwilling to have surgery, with biliary obstruction and at least one measurable lesion outside the bile ducts, plus good performance status and adequate organ function. - Key exclusions include ampullary cancer, brain metastases, major liver tumor burden (>50%), prior exposure to photosensitizers or PDT, prior systemic therapy in the recurrent/metastatic setting, unremovable biliary stents, active infections, and other conditions that could interfere with treatment.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma is being studied. Conditions: Uveal Melanoma, Melanoma, Metastatic Uveal Melanoma +1 • Eligibility: Inclusion Criteria: Cohort 1: Must have a confirmed diagnosis of metastatic Uveal Melanoma. * Patients will be eligible regardless of the number of prior systemic therapies received. *…. Goal: This is an open label study evaluating lifileucel (LN-144) in patients with metastatic uveal melanoma. Phase/Status/Sponsor: Unknown phase; RECRUITING; Memorial Sloan Kettering Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Clinical Trial of OMTX705 in Combination With Gemcitabine/Nab-Paclitaxel and Tislelizumab in Patients With Advanced/Metastatic Pancreatic Adenocarcinoma is being studied. Conditions: Pancreatic Adenocarcinoma Metastatic • Eligibility: Inclusion Criteria: 1. Capable of giving signed informed consent. 2. Male and female participant aged 18 years and older. 3. Participants must have histologically or cytologically confirmed PDAC:…. Goal: This is a Phase 1b dose escalation trial of OMTX705, an anti-fibroblast activation protein (FAP) antibody-drug conjugate (ADC), in combination with gemcitabine/nab-paclitaxel and tislelizumab in patients with advanced/metastatic pancreatic ductal adenocarcinoma (PDAC). The trial will be conducted in two parts (Part 1 and Part 2). Phase/Status/Sponsor: Unknown phase; RECRUITING; Oncomatryx Biopharma S.L..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma is being studied. Conditions: Advanced (Unresectable or Metastatic) Melanoma • Eligibility: Inclusion Criteria: 1. Age ≥18 years at the time of signing the informed consent (or adulthood where the legalage of majority in the country is established \>18 years).…. Goal: This is a randomised, multicentre, multinational, double-blind, integrated study to sompare the pharmacokinetics, efficacy, safety, and immunogenicity of MB11 versus Opdivo® in subjects with previously untreated advanced (unresectable or Metastatic) Melanoma Phase/Status/Sponsor: Unknown phase; RECRUITING; mAbxience Research S.L..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tests whether camrelizumab (SHR-1210) plus apatinib can extend overall survival in people with advanced gastric or gastroesophageal junction adenocarcinoma whose disease progressed after first-line platinum-based therapy. It targets adults with metastatic or unresectable disease and PD-L1–positive tumors, who have good performance status and adequate organ function. The trial aims to learn if the combination is more effective and safe, and will collect PD-L1 biomarker data from tumor tissue. Key exclusions include active CNS metastases or autoimmune disease, uncontrolled cardiovascular issues, recent major GI bleeding or thrombosis, prior anti-PD-1/PD-L1 or VEGFR inhibitor therapy, and recent systemic therapy or unresolved adverse events.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer is being studied. Conditions: Previously Treated Non-Small Cell Lung Cancer • Eligibility: 5.1 Registration Step 0: 1. Patients who need the fresh biopsy must also submit whole blood for ctDNA testing (see Section 15.3). These patients must be registered to…. Goal: This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. Phase/Status/Sponsor: Unknown phase; RECRUITING; SWOG Cancer Research Network.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry is being studied. Conditions: Cancer, Metastatic, Cancer, Cancer of Pancreas +40 • Eligibility: Inclusion Criteria: * Pts with solid and hematological malignancies; * Pts cancer-related biomarkers, gene variants, fusion and rearrangements (by immunohistochemistry, PCR, FISH or NGS): PD-L1, MSI (MMR), Claudin18.2,…. Goal: International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention. Phase/Status/Sponsor: Unknown phase; RECRUITING; Massive Bio, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Palbociclib and Pembrolizumab In Central Nervous System Metastases is being studied. Conditions: Metastatic Malignant Neoplasm to Brain, Recurrent Brain Metastases, Progressive Brain Metastases • Eligibility: Inclusion Criteria: * Participants must have histologically or cytologically confirmed disease from any solid tumor (Cohort 1) * Participants must have histologically or cytologically confirmed disease from breast…. Goal: This research study is studying This research study is studying the efficacy and safety of the following study drugs as a possible treatment for recurrent central nervous system (CNS) metastases: * Palbociclib alone (Cohort 1) * The combination of palbociclib and pembrolizumab (Cohort 2) Pfizer and Merck, pharmaceutical companies, are supporting this research study by providing the study drugs as well as funding for research activities. Phase/Status/Sponsor: Unknown phase; RECRUITING; Massachusetts General Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer is being studied. Conditions: BRAF V600 Colorectal Cancer • Eligibility: Inclusion Criteria: * Age ≥18 years and ≤75 years * Histologically confirmed metastatic colorectal adenocarcinoma * BRAF V600E mutation confirmed by tissue pathology or ctDNA testing (PCR or…. Goal: The goal of this clinical trial is to learn if Iparomlimab and Tuvonralimab combined with bevacizumab and FOLFIRI (IB-FOLFIRI) is safe and effective in treating adults with BRAF V600E-mutant metastatic colorectal cancer (mCRC). The main questions it aims to answer are: Does IB-FOLFIRI improve clinical outcomes compared with historical outcomes in this population? Phase/Status/Sponsor: Unknown phase; RECRUITING; Sun Yat-sen University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A First-in-Human Escalation and Expansion Study of Patients With Advanced Solid Tumors is being studied. Conditions: Solid Tumors, Gastric Cancer, Esophagogastric Juction Cancer +1 • Eligibility: Inclusion Criteria Patients who meet ALL the following inclusion criteria will be eligible to participate in the study: 1. ≥18 years of age. 2. Histologically confirmed, locally advanced,…. Goal: The goal of this clinical trial is to learn if the investigational drug (JR8603) is safe and effective in treating patients with solid tumors after their initial rounds of treatment with other drugs did not work. Phase/Status/Sponsor: Unknown phase; RECRUITING; JiaRay Group.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of NX-1607 in Adults With Advanced Malignancies is being studied. Conditions: Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer +11 • Eligibility: Key Inclusion Criteria: * Age ≥ 18 years. * Measurable disease per disease-specific response criteria. * Patients must have disease that is metastatic or unresectable and have received…. Goal: This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies. Phase/Status/Sponsor: Unknown phase; RECRUITING; Nurix Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The study is testing a combination of pembrolizumab and lenvatinib for people with anaplastic thyroid cancer. It is recruiting adults in Russia whose cancer cannot be fully removed by surgery and who have a reasonably good performance status. The trial aims to find out whether this drug combination can effectively treat the cancer and how safe it is, with responses measured using iRECIST criteria. Key exclusions include BRAF V600 mutations without prior targeted therapy, significant bleeding risk or invasion into large vessels, pregnancy, and poor functional status.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Adebrelimab Maintenance Therapy for LS-SCLC Post Induction Chemo-Adebrelimab Plus CRT or CRT Alone is being studied. Conditions: Localized Small Cell Lung Cancer • Eligibility: Inclusion Criteria: 1. Age: 18-75 years old, male or female; 2. Patients with pathologically confirmed localized small cell lung cancer (as defined by the Veterans Administration Lung Study…. Goal: Observation and Evaluation of the Efficacy and Safety of Adalimumab Combined with Chemotherapy Followed by Radiotherapy or Radiotherapy Alone as First-Line Treatment for Limited-Stage Small Cell Lung Cancer Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Peking University Cancer Hospital & Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma is being studied. Conditions: Melanoma Stage III, Melanoma Stage IV, BRAF V600 Mutation • Eligibility: Inclusion Criteria: * Age ≥ 18 years at the time of informed consent * Histologically confirmed diagnosis of melanoma. Any primary or unknown origin is permitted. * Melanoma…. Goal: The purpose of this study is to assess rate of disease relapse and hazard rate of disease relapse after neoadjuvant therapy based on the statuses of pathologic complete response or non-pathologic complete response, and postoperative adjuvant therapy. Phase/Status/Sponsor: Unknown phase; RECRUITING; H. Lee Moffitt Cancer Center and Research Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer is being studied. Conditions: Cutaneous Squamous Cell Carcinoma, SCC - Squamous Cell Carcinoma, Basal Cell Carcinoma +16 • Eligibility: Inclusion Criteria: * Age 18 or over * Histologically or cytologically documented advanced or metastatic cancer that has relapsed from or is refractory to standard treatment in two…. Goal: Participants of this study will have a diagnosis of a solid tumor cancer that has come back to its original location or spread beyond its original location (advanced), came back (relapsed) or worsened (refractory) after standard treatments, or no standard treatments are available for the participants' cancer. The purpose of this study if to find the highest dose of MQ710 that causes few or mild side effects in participants with a solid tumor cancer diagnosis. Phase/Status/Sponsor: Unknown phase; RECRUITING; Memorial Sloan Kettering Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer is being studied. Conditions: Colorectal Cancer • Eligibility: Inclusion Criteria for Cohort A and B: * Age ≥70 years. * Eastern Cooperative Oncology Group (ECOG) performance status 0 -2 * Have histologically proven localized or locally…. Goal: The purpose of this study is to evaluate the safety and clinical activity of cemiplimab and the combination of cemiplimab/fianlimab in microsatellite unstable localized or locally advanced colorectal cancer diagnosed in patients age 70 or greater or in patients age 18 or greater considered poor candidates for surgery. Phase/Status/Sponsor: Unknown phase; RECRUITING; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer is being studied. Conditions: Advanced Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage IIA Pancreatic Cancer AJCC v8 +4 • Eligibility: Inclusion Criteria: * Documented informed consent by the participant * Willingness to provide tissue and blood samples for correlative studies * Age: \>= 18 years * Eastern Cooperative…. Goal: This phase II trial studies the effects of lenvatinib and pembrolizumab maintenance therapy in treating patients with pancreatic cancer that has spread to other places in the body (advanced) and cannot be removed by surgery (unresectable). Lenvatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Phase/Status/Sponsor: Unknown phase; RECRUITING; City of Hope Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This is a single-arm trial testing whether adding pembrolizumab to the standard chemotherapy drugs gemcitabine and cisplatin given before surgery improves outcomes for potentially resectable intrahepatic cholangiocarcinoma. - It targets adults with high-risk disease confined to the liver, bile ducts, and nearby lymph nodes who are planned for curative surgery. - The study aims to see if pembrolizumab improves recurrence-free survival after surgery and increases major pathologic response, while also evaluating safety and overall survival, plus various biomarker and immune studies. - Key exclusions include prior anti-PD-1/PD-L1 therapy, prior systemic therapy for ICC, active CNS metastases, active infection or autoimmune disease requiring systemic treatment, pregnancy or lack of contraception, and certain hepatitis B/C or HIV conditions.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases is being studied. Conditions: Brain Metastases, Tumor • Eligibility: Inclusion Criteria: Patients are eligible to be included in the study only if all the following criteria apply: 1. Male/female patients who are at least 18 years of…. Goal: This is a single-center, open-label, multi-cohort Phase II study evaluating the efficacy and safety of pembrolizumab in combination with lenvatinib in patients with solid tumors and brain metastases. The study will be comprised of 3 patient cohorts: triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), and solid tumor types other than TNBC and NSCLC. Phase/Status/Sponsor: Unknown phase; RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This is a phase 2, recruiting study testing a combination of all-trans retinoic acid (ATRA) and cemiplimab in adults with metastatic or locally advanced, unresectable leiomyosarcoma (LMS) that has progressed after standard therapy. - It aims to learn how well the combo works by measuring objective responses and survival, using RECIST 1.1 and iRECIST, and to assess safety. - Treatment starts with ATRA for 3 cycles, then cemiplimab IV every 3 weeks for three cycles, followed by cemiplimab alone; cohorts are guided by a Bayesian Optimal Phase II design (BOP2). - Eligible participants are adults with LMS with measurable disease and adequate organ function; prior PD-1/PD-L1 therapy is allowed; key exclusions include active autoimmune disease, symptomatic CNS metastases, cirrhosis (Child-Pugh B), pregnancy, and recent major surgery or uncontrolled infection.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors is being studied. Conditions: Solid Tumor • Eligibility: Inclusion Criteria: 1. Must be ≥ 18 years of age when signing informed consent. 2. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 without deterioration in…. Goal: This is a phase Ib/II, open, dose-escalation and expansion study of an anti-PD1/TIM3 bispecific antibody，LB1410 in combination with an anti-Claudin18.2/IL-10 fusion protein, LB4330 in patients with advanced or metastatic solid tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; L & L Bio Co., Ltd., Ningbo, China.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Purpose of This Study is to Evaluate the Safety, Tolerability and Efficacy of TMT101 Injection Monotherapy in Patients With Advanced Pancreatic Cancer or Non-small Cell Lung Cancer(NSCLC) is being studied. Conditions: Non-small Cell Lung Cancer • Eligibility: Inclusion Criteria: 1. Agrees to follow the trial protocol and visit schedule, has signed informed consent; 2. Subjects must be ≥18 years of age at time of informed…. Goal: This is a first-in-human, single-arm, open-label, dose escalation prospective phase I clinical study to evaluate the Safety, Tolerability and Efficacy of TMT101 Injection Alone in patients with Unresectable, Metastatic or Advanced pancreatic cancer or Non-small Cell Lung Cancer(NSCLC) after Standard Treatment Failure. The primary objective is to evaluate the safety and tolerability of TMT101 Injection as monotherapy in patients with advanced pancreatic cancer and NSCLC, and to determine the recommended therapeutic dose (RD) of TMT101 Injection as monotherapy Phase/Status/Sponsor: Unknown phase; RECRUITING; Peking Union Medical College Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer is being studied. Conditions: Carcinoma, Non-Small-Cell Lung • Eligibility: Inclusion criteria: * Participant must have histologically or cytologically confirmed metastatic NSCLC characterized by a KRAS G12C mutation at the time of enrollment. For Phase 1: Participant must…. Goal: The main purpose of this study is to find out the most suitable dose (recommended phase 2 combination dose \[RP2CD\]) of amivantamab and olomorasib combination therapy and to assess how well the combination slows down or prevents the growth of tumors in participants with KRAS G12C mutant metastatic non-small cell lung cancer (NSCLC: the most common type of lung cancer; metastatic: has spread to other parts of the body; KRAS G12C mutant: mutation \[change\] in the kirsten rat sarcoma viral oncogene homolog \[KRAS\] gene in tumor cells in which glycine \[G\] at position 12 is replaced with cystine \[C\]). Phase/Status/Sponsor: Unknown phase; RECRUITING; Janssen Research & Development, LLC.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma is being studied. Conditions: Glioblastoma Multiforme • Eligibility: Inclusion Criteria: * Newly-diagnosed adults with WHO (World Health Organization) Grade IV Glioblastoma or gliosarcoma based on histopathological or molecular criteria who had carmustine wafers placed at resection…. Goal: The purpose of the study is to evaluate the safety and survival of carmustine wafers and radiation and retifanlimab with or without temozolomide (TMZ) in newly-diagnosed adult subjects with glioblastoma multiform after carmustine wafer placement. Phase/Status/Sponsor: Unknown phase; RECRUITING; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma is being studied. Conditions: Extrahepatic Cholangiocarcinoma, Unresectable Perihilar or Ductal CCA • Eligibility: Inclusion Criteria: 1. Patient\* has given written informed consent. 2. Patient is ≥ 18 years of age at time of signing the written informed consent. 3. Patient is…. Goal: The present clinical trial is a prospective, investigator-initiated, single-arm, open-label, multicenter phase II trial. Patients with unresectable perihilar and/or ductal CCA with indication for bile duct stenting and palliative systemic therapy as determined by the local multidisciplinary team (MDT), who already resolved cholestasis due to RFA + Stent will be enrolled. Phase/Status/Sponsor: Unknown phase; RECRUITING; Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The trial is a pilot feasibility study testing a new multimodal treatment for unresectable malignant pleural mesothelioma, using intrapleural photodynamic therapy delivered during video-thoracoscopy, followed by nivolumab immunotherapy, in about 20 patients. It is for adults whose mesothelioma cannot be surgically removed and who have progressed after one or two lines of platinum-based chemotherapy, or who cannot have chemotherapy. The study aims to learn whether this combination can be delivered safely and feasibly, and to gather early information about its potential clinical benefit. Eligible participants are those with good performance status and measurable disease accessible for PDT, while key exclusions include pregnancy, prior anti-PD-1/PD-L1 treatment in the last five years, contraindications to 5-ALA/PDT or thoracoscopy, and significant organ dysfunction.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC) is being studied. Conditions: Non Small Cell Lung Cancer • Eligibility: Inclusion Criteria: * Have a full understanding of the study content, process, and possible adverse reactions before the study, and sign the informed consent form (ICF); voluntarily participate…. Goal: The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Phase/Status/Sponsor: Unknown phase; RECRUITING; Shanghai Henlius Biotech.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Cryoablation Combined With Lenvatinib Plus QL1706 (Iparomlimab/Tuvonralimab) in Patients With Advanced Intrahepatic Cholangiocarcinoma is being studied. Conditions: Intrahepatic Cholangiocarcinoma (Icc) • Eligibility: Inclusion Criteria: * Written informed consent obtained. * Age ≥ 18 years at time of study entry. * Participants must have unresectable or metastatic histologically or cytologically confirmed…. Goal: This study will evaluate the efficacy and safety of cryoablation combined with lenvatinib plus QL1706 (iparomlimab/tuvonralimab) in patients with advanced Intrahepatic Cholangiocarcinoma (ICC) who have progressed after first-line treatment. Phase/Status/Sponsor: Unknown phase; RECRUITING; Fudan University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP) is being studied. Conditions: Glioblastoma, Glioblastoma, WHO Grade IV • Eligibility: Inclusion Criteria: * Histologic confirmation of glioblastoma, WHO Grade IV (GBM variants are allowed; Lower grade gliomas that have been transformed to GBM will be considered newly diagnosed…. Goal: Glioblastoma multiforme (GBM) is the most common and deadliest primary malignant neoplasm of the central nervous system in adults. Despite an aggressive multimodality treatment approach including surgery, radiation therapy and chemotherapy, overall survival remains poor. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; University of Florida.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis is being studied. Conditions: Melanoma Stage III, Melanoma Stage IV, Skin Cancer Stage III +4 • Eligibility: Inclusion Criteria: * Age ≥ 18 * Stage III/IV skin cancer * Treatment with CTLA-4 inhibitor alone or in combination with PD-1or PD-L1 blockade within the past 8…. Goal: The goal of this clinical trial is to compare the safety and effectiveness of infliximab compared to steroids for the treatment of immune checkpoint inhibitor-induced colitis (ICI colitis) in patients with stage III/IV skin cancer. The main questions this study aims to answer are: * How many patients treated with infliximab experience steroid-free disease resolution after 7 weeks? Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Massachusetts General Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Prospective, Single-Arm, Phase II Clinical Study of Neoadjuvant Therapy With Pucotenlimab, Lenvatinib, and Temozolomide for Resectable Head and Neck Mucosal Melanoma (PLT-NAT-HNMM-II) is being studied. Conditions: Head and Neck Mucosal Melanomas • Eligibility: Inclusion Criteria: * Age 18 to 75 years, regardless of gender. * Histologically confirmed primary, resectable Head and Neck Mucosal Melanoma (HNMM), with measurable lesions (spiral CT scan…. Goal: This study aims to conduct a prospective clinical trial investigating the use of pucotenlimab in combination with lenvatinib and temozolomide as neoadjuvant and postoperative adjuvant therapy for resectable oral and head and neck mucosal melanoma. The primary objectives are to evaluate the safety and efficacy of this combination regimen in the neoadjuvant treatment of head and neck mucosal melanoma. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests a first-line treatment for unresectable intrahepatic cholangiocarcinoma using FOLFOX-based hepatic arterial infusion chemotherapy with donafenib and pucotenlimab. - It is a prospective, open-label, single-arm phase II study and is not yet recruiting. - The primary goal is to measure the objective response rate, with secondary goals including progression-free survival, overall survival, disease control rate, and safety. - Eligible participants are adults up to 75 years old; key exclusions include prior anti-PD-1/PD-L1 therapy, active CNS metastases, autoimmune disease requiring systemic treatment, active infection, HBV DNA > 2000 IU/mL, HIV, syphilis, and pregnancy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma is being studied. Conditions: Resectable Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Ductal Adenocarcinoma • Eligibility: Inclusion Criteria: * Age ≥18 years. * Has pancreatic ductal adenocarcinoma * Has resectable disease at the time of diagnosis * Has not received any systemic therapy for…. Goal: This study will test the effectiveness (anti-tumor activity), safety, and ability to increase the body's immune system to fight pancreatic cancer by combining standard chemotherapy before and after surgery, with study drug PD-1 antibody, pembrolizumab, with and without study drug, focal adhesion kinase inhibitor (FAK), defactinib, in people with "high risk" resectable (surgically removable) pancreatic cancer. The purpose of this study is to evaluate if reprograming the tumor microenvironment by targeting FAK following chemotherapy can potentiate anti-programmed death-1 (PD-1) antibody. Phase/Status/Sponsor: Unknown phase; COMPLETED; Lei Zheng.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors is being studied. Conditions: Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC) • Eligibility: Key Inclusion Criteria: mCRPC cohorts (men): 1. Men with histologically or cytologically confirmed adenocarcinoma of the prostate without pure small cell carcinoma. 2. PSA value at screening ≥4…. Goal: The main purpose of this study is to determine the safety, tolerability (how the body reacts to the drug\[s\]) and effectiveness (ability to treat the cancer) of REGN5678 (Nezastomig) alone, or in combination with cemiplimab. The study has 2 parts. Phase/Status/Sponsor: Unknown phase; RECRUITING; Regeneron Pharmaceuticals.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests a drug called MGC028 in adults whose ADAM9-expressing solid tumors are relapsed or refractory, unresectable, locally advanced, or metastatic. - It uses dose escalation to find a safe dose and to describe safety and side effects, including any dose-limiting toxicities and the highest dose that can be given safely. - The trial also aims to learn whether MGC028 can shrink tumors, keep cancer from growing, or control disease in these advanced cancers. - Cancers eligible for participation include NSCLC adenocarcinoma, cholangiocarcinoma, colorectal cancer, and pancreatic cancer with specific prior-treatment criteria; key exclusions include active brain metastases, prior ADAM9-targeted therapy, recent major cancer treatment, organ transplant, infection, and pregnancy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors is being studied. Conditions: Solid Tumours, Sarcoma, HNSCC +9 • Eligibility: Inclusion Criteria: 1. Histologically or cytologically confirmed disease, locally advanced or metastatic: For Phase 1a: Solid tumor with a COX2-associated immunosuppressive pathway, for which standard treatment options are…. Goal: The purpose of this study is to investigate the study drug, OKN4395, administered alone and in combination with pembrolizumab. The overall objectives of this study are to determine the safety and tolerability (degree to which side effects of a drug can be tolerated) of OKN4395 alone and in combination with pembrolizumab, OKN4395 and metabolites (broken-down substances) of OKN4395 levels in the blood, and antitumor activity of OKN4395 alone and in combination with pembrolizumab. Phase/Status/Sponsor: Unknown phase; RECRUITING; Epkin.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer is being studied. Conditions: Combined Hepatocellular Carcinoma and Cholangiocarcinoma, Stage III Liver Cancer, Stage IV Liver Cancer • Eligibility: Inclusion Criteria: * Patient must be \>= 18 years of age * Patient must have a histologically confirmed diagnosis of combined hepatocellular carcinoma-cholangiocarcinoma (cHCC-CC) at the local laboratory…. Goal: This phase II trial compares the effect of adding bevacizumab and atezolizumab to gemcitabine and cisplatin (chemotherapy) versus chemotherapy and atezolizumab in treating patients with liver cancer that cannot be removed by surgery (unresectable) or that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome is being studied. Conditions: Chronic Lymphocytic Leukemia, Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia +2 • Eligibility: Inclusion: 1. Patients will have a diagnosis of CLL or SLL or RTand are: a) Cohort 1: Patients with treatment naïve CLL/SLL who meet IWCLL criteria for treatment…. Goal: This phase II trial studies how well atezolizumab, obinutuzumab, and venetoclax work in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma or Richter syndrome that has come back (recurrent) or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as atezolizumab and obinutuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests a combination of cisplatin, docetaxel, and pembrolizumab (PCD) in people with newly diagnosed stage II–III laryngeal cancer. It aims to measure the clinical benefit after 2 cycles and the pathologic complete response after 4 cycles of PCD. Secondary goals include safety, the 2-year rate of preserving the larynx, relapse-free and overall survival, and patient-reported and swallowing outcomes. Eligible participants are untreated, stage II–III laryngeal cancer patients; key exclusions include prior anti-PD-1/PD-L1 therapy, active autoimmune disease needing systemic treatment, active infections or immunodeficiency, HIV or hepatitis B/C, pregnancy, and recent systemic cancer therapy or certain live vaccines.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial) is being studied. Conditions: Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7 • Eligibility: Inclusion Criteria: * Age \>= 18 years * Patients must have undergone complete surgical resection of their stage IB (\>= 4 cm), II or IIIA NSCLC according to…. Goal: This phase III ALCHEMIST treatment trial studies how well nivolumab after surgery and chemotherapy work in treating patients with stage IB-IIIA non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This study tests the combination of nivolumab and ipilimumab in adults with rare cancers to see if it can shrink tumors or slow their growth. - It includes many different rare tumor types in separate groups, plus a PD-L1–amplified cohort that uses nivolumab alone, and it measures how often tumors respond using standard criteria. - The trial also looks at safety, overall survival, and progression-free survival across cohorts. - Eligible participants must have progressed after prior therapy and generally cannot have active brain metastases or uncontrolled autoimmune disease; some cohorts have additional specific requirements or exclusions.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tests whether nivolumab given with multi-fraction stereotactic radiosurgery, with or without ipilimumab, is safe and potentially effective for adults with recurrent WHO grade II-III meningioma that has returned after prior radiation. It is a phase I/II trial that starts with dose escalation to find a safe maximum dose, followed by a phase II portion where participants are randomized to two treatment cohorts. The main goals are safety and the maximum tolerated dose, and to assess tumor response on MRI. Secondary goals include duration of response, progression-free survival, overall survival, and exploratory immune and tumor genetic studies to identify biomarkers and resistance mechanisms. Key exclusions include recent chemotherapy or radiation to the target site, prior checkpoint inhibitor therapy, active autoimmune disease, pregnancy, and uncontrolled illness.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This study tests adding tazemetostat to pembrolizumab for adults with locally advanced or metastatic urothelial carcinoma (cisplatin-resistant or platinum-ineligible). - The main goal is to find a safe dose for the combination and to see how well it works, including response rate, progression-free survival, and immune-related tumor responses. - The trial also includes correlative studies using tissue and blood to learn which patients may respond. - Key exclusions include prior PD-L1 or EZH2 inhibitors, active brain metastases (unless previously treated and stable), pregnancy or breastfeeding, and certain uncontrolled illnesses or recent cancer therapies.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Clinical Study of CBG131 CAR-T Cell Injection for the Treatment of CLDN18.2-Positive Advanced Gastric and Pancreatic Cancer is being studied. Conditions: Advanced Gastric and Pancreatic Cancer • Eligibility: Inclusion Criteria: 1. Age 18-70 years (inclusive) at the time of informed consent; sex unrestricted. 2. Voluntary participation: the subject (or legally authorized representative) must provide written informed…. Goal: The goal of this clinical trial is to learn if CBG131 works to treat advanced gastric cancer or pancreatic cancer in adults whose tumors are CLDN18.2-positive. It will also learn about the safety of CBG131 and find the best dose to use. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; First Affiliated Hospital of Wenzhou Medical University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Safety and Preliminary Efficacy Evaluation of LC-K76 Plus Anti-PD-1 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) is being studied. Conditions: mCRPC • Eligibility: Inclusion Criteria: 1. Male, aged 18 to 85 years. 2. Histologically confirmed prostate adenocarcinoma, without small cell carcinoma components. 3. Metastatic Castration-Resistant Prostate Cancer (mCRPC) with disease progression…. Goal: This open-label, single-arm study evaluates the safety and preliminary efficacy of LC-K76 combined with Tislelizumab and ADT in 10 patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) who progressed on prior therapies. Participants will receive oral LC-K76 and intravenous Tislelizumab for a 24-week treatment period. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Shanghai Changzheng Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer is being studied. Conditions: Prostate Cancer • Eligibility: Inclusion Criteria: * Male participants who are at least 18 years of age on the day of signing informed consent with histologically confirmed diagnosis of prostate adenocarcinoma. *…. Goal: This is a phase I/II study investigating the combination of 225Ac-J591 (a drug that can deliver radiation to prostate cancer cells) with pembrolizumab (immunotherapy, a drug that increases the immune system's ability to destroy cancer cells). This study will assess whether 225Ac-J591 + pembrolizumab + androgen receptor inhibitor (ARI) is more effective against prostate cancer than pembrolizumab + ARI alone. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Weill Medical College of Cornell University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tests a combination of guadecitabine (a chemotherapy) and atezolizumab (an immunotherapy) in adults with advanced myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) that has relapsed or is refractory to prior treatment, and it includes newly diagnosed MDS as well. It is a two-part study (phase I dose-escalation followed by phase II) to find a safe dose and then evaluate how well the combination works. The trial aims to assess safety and tolerability and to measure efficacy, including overall survival, duration of response, and changes in transfusion dependence. Eligibility requires prior treatment with azacitidine or decitabine with progression or loss of response, plus certain health criteria; key exclusions include active autoimmune disease, active infection, prior PD-1/PD-L1 or CTLA-4 therapy, and pregnancy. The study is currently active but not recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy is being studied. Conditions: Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Breast Inflammatory Carcinoma +2 • Eligibility: Inclusion Criteria: 1. Is willing and able to provide written informed consent for the trial. 2. Is a female or male and \>/= 18 years of age 3.…. Goal: This phase II trial studies how well pembrolizumab works in treating patients with hormone receptor positive inflammatory breast cancer that has not spread to other parts of the body, who are receiving hormone therapy and did not achieve a pathological complete response to chemotherapy. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery is being studied. Conditions: Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7 +4 • Eligibility: Inclusion Criteria: * PRE-REGISTRATION- INCLUSION CRITERIA * Diagnosis of unresectable stage III or metastatic melanoma (stage IV) not amenable to local therapy * At least one non-nodal lesion…. Goal: This phase I trial studies the best dose of ibrutinib when given together with pembrolizumab in treating patients with stage III-IV melanoma that cannot be removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Mayo Clinic.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is a not-yet-recruiting, single-arm Phase II trial testing whether Sintilimab plus Bevacizumab and AG chemotherapy can be given as first-line treatment for adults with unresectable locally advanced or metastatic cholangiocarcinoma. The study is for adults aged 18–75 who have surgically unresectable disease, no prior systemic therapy (except some postoperative therapy more than 6 months ago), and at least one measurable lesion. It aims to learn how often tumors respond, how many patients have disease control, how long responses last, overall survival, and safety, and it will also explore biomarker signals like PD-L1 and tumor mutational burden. Key exclusions include prior anti-PD-1/PD-L1 therapy, active autoimmune disease needing systemic treatment, HIV, active HBV or HCV infection, pregnancy, high bleeding risk, and recent major surgery.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Fruquintinib in the Treatment of Immunodominant pMMR/MSS Metastatic Colorectal Cancer That Has Failed Second-line or Above Treatment is being studied. Conditions: Colorectal Cancer • Eligibility: Inclusion Criteria: 1. Have a full understanding of this study and voluntarily sign the informed consent form; 2. Aged 18 - 75 years; 3. Patients must be pathologically…. Goal: The goal of this clinical trial is to explore the preliminary efficacy and tolerability of Aipalolitovorelizumab (QL1706) in combination with fruquintinib for the treatment of metastatic colorectal cancer patients with immunodominant pMMR/MSS type who have failed second-line or above treatment. It is an open-label, single-arm, single-center phase II trial. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Harbin Medical University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study is being studied. Conditions: Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Carcinoma in Situ of Bladder +1 • Eligibility: Inclusion Criteria: 1. Age ≥18 years; sex: all; signed written informed consent by the participant or legally authorised representative. 2. Histologically confirmed high-risk non-muscle-invasive bladder cancer (HR-NMIBC), defined…. Goal: This open-label, randomised, multicentre, phase 2 study (OHAI-NMIBC-01) compares toripalimab plus sequential intravesical gemcitabine followed by mitomycin C (GEM→MMC) with toripalimab alone in adults with BCG-unresponsive or BCG-intolerant high-risk non-muscle-invasive bladder cancer (HR-NMIBC). Two prespecified cohorts are analysed: (1) CIS cohort (CIS with/without Ta/T1) and (2) non-CIS cohort (high-risk Ta/T1 without CIS). Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; First Affiliated Hospital of Wenzhou Medical University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is a randomized, open-label, single-center trial testing two first-line treatments for advanced intrahepatic cholangiocarcinoma (ICC). It compares Iparomlimab and Tuvonralimab plus GC with Sintilimab plus GC to see which therapy is more effective and safe as initial treatment. The main goal is to measure the 6-month progression-free survival rate, with secondary goals including response rate, duration of response, time to response, progression-free survival, overall survival, and safety. About 104 adults aged 18–75 with unresectable or metastatic ICC who have not yet had systemic therapy for advanced disease will be enrolled; key exclusions include active autoimmune disease needing systemic therapy, HIV, active hepatitis B or C, recent systemic corticosteroid or immunosuppressant use, pregnancy or breastfeeding, prior immunotherapy for advanced disease, and certain uncontrolled conditions.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma is being studied. Conditions: Advanced Melanoma • Eligibility: Inclusion Criteria: To participate in the study, participants must meet all the following inclusion criteria: Cohort A only: 1. Prior treatment with anti-PD-(L)1 therapy (for example, pembrolizumab or…. Goal: This study is an open-label, 2-part, Phase 2, multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetic profiles of botensilimab as monotherapy and in combination with balstilimab in participants with advanced cutaneous melanoma refractory to checkpoint inhibitor therapy. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Agenus Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations is being studied. Conditions: Intrahepatic Cholangiocarcinoma (Icc), Advanced Cholangiocarcinoma • Eligibility: Inclusion Criteria: 1. ≥ 18 years of age at the time of signing the informed consent form (ICF). 2. Histologically or cytologically confirmed intrahepatic cholangiocarcinoma. 3. Subjects diagnosed…. Goal: This is an open-label, randomized, controlled, multicenter, phase III clinical study designed to evaluate the efficacy and safety of TT-00420 tablets as monotherapy versus chemotherapy in subjects with unresectable advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions/rearrangements or mutations, who have experienced recurrence or progression after prior first-line systemic chemotherapy. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; TransThera Sciences (Nanjing), Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors is being studied. Conditions: HNSCC, Melanoma, Gynecologic Cancer +3 • Eligibility: Inclusion Criteria * Participants must have signed and dated a current IRB/IEC approved written informed consent form in accordance with regulatory and institutional guidelines. Patients must have the…. Goal: The subject of this study is the adoptive transfer of selected autologous tumor infiltrating lymphocytes (TIL) after in vitro expansion for the treatment of solid tumor malignancies. The TIL selection process is based on evidence showing that CD8+ TIL which co-express both CD39 and CD103 harbor the bulk of tumor-reactivity and that the remaining CD8 TIL is mainly composed of non-tumor reactive bystander cells. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; AgonOx, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab is being studied. Conditions: Melanoma Stage III, Melanoma Stage IV • Eligibility: Inclusion Criteria: 1. Written Informed Consent and HIPAA Authorization 1. Subjects must have the nature of the study explained to them. 2. Subjects must be willing and able…. Goal: Cancers attract myeloid-derived suppressor cells (MDSCs) that prevent our own immune responses from destroying the cancer. This study will be the first study to begin to determine if the newly discovered drug SX-682 can block cancers from attracting MDSCs. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Syntrix Biosystems, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC) is being studied. Conditions: Lung Cancer, Non-small Cell Lung Cancer • Eligibility: Inclusion Criteria: * Willing and able to provide written informed consent/assent for the trial. * Be ≥ 18 years of age on day of signing informed consent. *…. Goal: The main purpose of this study is to see whether the combination of two drugs called pembrolizumab and vorinostat can help people with advanced lung cancer. Researchers also want to find out if the combination of pembrolizumab and vorinostat is safe and tolerable. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; H. Lee Moffitt Cancer Center and Research Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss is being studied. Conditions: Melanoma and Other Malignant Neoplasms of Skin, Metastatic Melanoma • Eligibility: Inclusion Criteria: 1. Be willing and able to provide written informed consent for the trial. 2. Be \>/= 18 years of age on day of signing informed consent.…. Goal: The goal of this clinical research study is to learn if GSK2636771 given in combination with pembrolizumab can help to control the disease in patients with refractory (has not responded to treatment) metastatic melanoma. The safety of this drug combination will also be studied. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy is being studied. Conditions: Extensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer • Eligibility: Inclusion Criteria (applicable to all participants unless otherwise specified): * Cohort 1 only: Have histologically or cytologically confirmed ES-SCLC (using the American Joint Committee on Cancer \[AJCC\]) tumor…. Goal: This is a Phase II, multi-site, open-label, parallel group study in participants with untreated extended-stage small-cell lung cancer (ES-SCLC) (Cohort 1) or small-cell lung cancer (SCLC) which has progressed on first- or second-line treatment (Cohort 2 and Cohort 3). This study will assess the safety, efficacy, and pharmacokinetics (PK) of BNT327. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; BioNTech SE.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is a Phase III, open-label, multicentre, randomized trial comparing dostarlimab with carboplatin-paclitaxel as first-line treatment for adults with MMR-deficient (MMRd/MSI-H) endometrial cancer that is recurrent or advanced. It is for women aged 18 and older with MMRd/MSI-H endometrial cancer who have measurable disease and ECOG 0-1. Randomization is 1:1 and stratified by prior adjuvant chemotherapy, prior pelvic radiotherapy, and whether the disease is newly diagnosed advanced/metastatic or relapse. Exclusion criteria include prior anti-PD-1/PD-L1 therapy, active brain metastases, certain active infections or autoimmune disease, and recent systemic anticancer therapy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The study tests whether adding serplulimab to FLOT chemotherapy improves the rate of complete tumor disappearance (pCR) in adults with stage III gastric adenocarcinoma. It compares serplulimab plus FLOT versus FLOT alone in a randomized design, for patients whose tumors are PD-L1 positive (CPS ≥ 1). Participants receive treatment every two weeks, have imaging at 4 and 8 weeks, then undergo surgery and may receive postoperative serplulimab with adjuvant chemotherapy or adjuvant chemotherapy alone. Key exclusions include HER2-positive tumors, MSI-H/dMMR, autoimmune disease, prior gastric cancer treatment, active infection or pregnancy. Status: ACTIVE_NOT_RECRUITING (the trial is active but not recruiting).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Randomized Trial of Surgical Decision-Making Guided by TDTP-RECIST is being studied. Conditions: Intrahepatic Cholangiocarcinoma (Icc), Conversion Therapy, TDTP-RECIST +1 • Eligibility: Inclusion Criteria: \- Subjects eligible to participate in this study must meet all of the following criteria: 1. Male or female aged 18-75 years; 2. Patients must provide…. Goal: This project aims to conduct a prospective, multicenter, randomized controlled clinical trial. The study plans to enroll 270 patients with locally advanced iCCA who have successfully undergone GOLP conversion therapy. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Shanghai Zhongshan Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The LOGIC trial tests whether adding cryoablation, with or without pembrolizumab, improves immune response and tumor control in high-risk, early-stage triple-negative breast cancer. It will enroll women aged 18 to 90 with clinical stage I/II disease and randomize them to three groups: standard neoadjuvant therapy with surgery, cryoablation followed by neoadjuvant therapy and surgery, or cryoablation plus a single dose of pembrolizumab before cryoablation followed by neoadjuvant therapy and surgery. The study will measure immune and tumor changes in blood and tissue (including TILs, T-cell subsets, and cytokines) at multiple time points. Key exclusions include autoimmune disease or chronic immunosuppression, prior immunotherapy, inflammatory breast cancer, pregnancy or breastfeeding, prior radiation, recent vaccination, and other primary cancers or investigational drug use. Status: NOT_YET_RECRUITING.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests a new combination therapy for malignant mesothelioma: iparomlimab and tuvonralimab (QL1706) given with chemotherapy. - It is for adults with MM who are not candidates for radical surgery or radiotherapy and meet other health criteria. - The study has two phases: a small Phase Ib safety run-in, followed by a Phase II expansion to measure effectiveness in first-line and second-line patients. - Exclusions include prior CTLA-4 inhibitors, recent immune-modulating therapy, and significant cardiovascular disease in the past 6 months.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Camrelizumab in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-negative Breast Cancer is being studied. Conditions: Breast Cancer • Eligibility: Inclusion Criteria: 1\) 18-65 Years, female; 2) Histologically documented Triple Negative Breast Cancer (TNBC) patients; 3) Previously untreated non-metastatic (M0) TNBC, T3-4NanyM0 или TanyN+M0 3) Promising radical surgical…. Goal: To explore the application of Camrelizumab with chemotherapy as neoadjuvant treatment of early-stage TNBC. Phase II clinical study of Camrelizumab in neoadjuvant treatment of early-stage TNBC is proposed. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Blokhin's Russian Cancer Research Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The trial tests whether adding peginterferon alfa-2b to standard nucleos(t)ide analogue therapy can reduce recurrence of HBV-related liver cancer after radical treatment. - It is for adults aged 18-70 who are HBV surface antigen positive and have hepatocellular carcinoma treated with surgery or ablation, with good liver function (BCLC 0-A, Child-Pugh A). - The study is single-center, non-randomized, open-label, comparing NAs alone versus NAs plus peginterferon alfa-2b to see if it lowers the 3-year recurrence rate and may improve cure. - Participants will undergo regular imaging and blood tests every few months to monitor recurrence and safety. - Key exclusions include prior systemic cancer treatments, other active cancers, allergy to interferon, severe liver or kidney disease, autoimmune disease, pregnancy, or participation in other trials.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC is being studied. Conditions: Non-squamous Non-small-cell Lung Cancer • Eligibility: Inclusion Criteria: * Signed Informed Consent Form (ICF) * Age ≥ 18 years at time of signing ICF * Ability to comply with the study protocol, in the…. Goal: To evaluate the efficacy of tiragolumab with atezolizumab and bevacizumab in previously-treated advanced non-squamous NSCLC. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Georgetown University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This is a phase II, single-arm trial testing a combination of tremelimumab with durvalumab (STRIDE) plus gemcitabine and cisplatin for adults with locally advanced unresectable or metastatic combined hepatocellular-cholangiocarcinoma (cHCC-CCA). - The study aims to learn about the safety of this regimen and whether it can shrink or control tumors, with regular disease assessments and treatment continuing until progression or toxicity. - Participants should be adults with measurable disease and adequate organ function; the study is not yet recruiting. - Key exclusions include active brain metastases, severe autoimmune disease, active infection, prior immunotherapy or gemcitabine/cisplatin for this disease, and pregnancy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) is being studied. Conditions: Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma +3 • Eligibility: Inclusion Criteria: * Participants must be assigned to S1900E. Assignment to S1900E is determined by the LUNGMAP protocol genomic profiling using the FoundationOne assay. Biomarker eligibility for S1900E…. Goal: This phase II Lung-MAP treatment trial studies the effect of AMG 510 in treating non-squamous non-small cell lung cancer that is stage IV or has come back (recurrent) and has a specific mutation in the KRAS gene, known as KRAS G12C. Mutations in this gene may cause the cancer to grow. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; SWOG Cancer Research Network.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements is being studied. Conditions: Intrahepatic Cholangiocarcinoma • Eligibility: Inclusion Criteria: Patients must meet all of the following criteria to be eligible for the study: 1. Fully informed written consent and locally required authorization (European Union \[EU\]…. Goal: The study trial is a open-label, single-arm, multicenter phase II trial investigating the combined treatment of atezolizumab and derazantinib in patients with advanced intrahepatic cholangiocarcinoma with FGFR2 fusions/rearrangements Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

GYNORYLAQ-VLINIVAL is an early-phase, non-randomized, single-arm trial enrolling by invitation to test a personalized neoantigen vaccine for people with high-risk or recurrent endometrial cancer. The vaccine, called GYNORYLAQ-TM, is selected for each patient by the GYNORYLAQ-EC platform and given with individualized background cancer therapies chosen by the treating oncologist; the vaccine itself is investigational. The study aims to evaluate safety and tolerability and to assess the feasibility of manufacturing GMP-grade, patient-specific vaccine panels. Secondary goals include measuring vaccine-induced T-cell immune responses and exploring how the platform’s quantum/physics scores relate to clinical and immunologic outcomes. Eligibility requires confirmed high-risk or recurrent endometrial cancer with measurable disease; key exclusions include active uncontrolled infection, autoimmune disease requiring systemic immunosuppression, untreated CNS metastases, and pregnancy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers is being studied. Conditions: Refractory Metastatic Colorectal Cancer, Solid Tumor, Metastatic Microsatellite-stable Colorectal Cancer +3 • Eligibility: Diagnosis and Main Criteria for Inclusion/Exclusion: Inclusion Criteria Main Study - patients with MSS mCRC These criteria are applicable for both Dose Escalation and Expansion part of the…. Goal: This Phase Ib/IIa study comprises a Main Study and a Study Extension. The Main Study has been designed according to a 3+3 Dose Escalation/dose Expansion design in refractory pMMR-MSS mCRC patients. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Rottapharm Biotech.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A MultIceNTER Phase I Peptide VaCcine Trial for the Treatment of H3-Mutated Gliomas is being studied. Conditions: Newly Diagnosed H3-mutated Glioma • Eligibility: Inclusion Criteria: * Patients present with histologically confirmed diagnosis of an H3.1K27M or H3.3K27M-mutated diffuse midline glioma WHO grade IV (with or without measurable residual tumor after tumor…. Goal: The study "A MultIceNTER Phase I Peptide VaCcine Trial to Exploit NeoePitope-Specific T Cells for the Treatment of H3K27M-Mutated Gliomas - (INTERCEPT H3)" is a non-controlled, open-label, single arm, multicenter phase I trial involving patients with gliomas carrying an H3.1K27M or H3.3K27M mutation. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; German Cancer Research Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests a new combination therapy for HPV-16–associated head and neck cancer, using the ISA101b vaccine with pembrolizumab and cisplatin-based chemoradiotherapy. It is for adults newly diagnosed with intermediate-risk, HPV-16–positive oropharyngeal squamous cell carcinoma, with no distant metastasis. The study aims to learn whether this treatment improves survival, and there is no separate control group. Key exclusions include distant metastases, prior anti-PD-1/PD-L1 therapy, active autoimmune disease requiring systemic treatment, active infection, or pregnancy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The trial tests a combination of cryoablation, SHR-1701 (a PD-L1 and TGF-β blocker), and famitinib for advanced intrahepatic cholangiocarcinoma that has progressed after first-line treatment. - It aims to learn how effective and safe this treatment is in adults with unresectable or metastatic ICC. - To participate, you must be 18 or older, have measurable disease, and have failed one line of GemCis plus a PD-1/PD-L1 inhibitor. - The study is not yet recruiting, and key exclusions include significant heart disease, recent thrombosis, active autoimmune disease requiring systemic therapy, active infections, prior cryoablation, or recent major cancer treatment.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors is being studied. Conditions: Advanced Solid Tumors • Eligibility: Inclusion Criteria: * Have measurable disease per Response evaluation criteria in solid tumors version 1.1 (RECIST 1.1) as assessed by the local site investigator. * Have an Eastern…. Goal: Researchers are looking for a better way to treat people who have advanced solid tumors. Advanced solid tumors are types of cancer that may have spread to nearby tissue, lymph nodes, and/or to distant parts of the body and that are unlikely to be cured or controlled with currently available treatments. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Bayer.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer is being studied. Conditions: Non Small Cell Lung Cancer, Lung Cancer, Nsclc +2 • Eligibility: Inclusion Criteria: * Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.…. Goal: The purpose of this study is to see if Durvalumab and radiation therapy can delay the worsening of disease in patients with non-small cell lung cancer normally treated with sequential chemotherapy followed by radiation therapy. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Memorial Sloan Kettering Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC) is being studied. Conditions: Advanced Melanoma, Renal Cell Carcinoma • Eligibility: Inclusion Criteria: * 1\. At least 1 site of disease must be accessible to provide repeat biopsies for tumor tissue. The biopsy may be waived if not feasible…. Goal: This study is a Phase 1, open-label, single institution, dose escalation and dose expansion study to evaluate the efficacy, safety, and tolerability of APX005M in combination with nivolumab and ipilimumab in patients with advanced melanoma and RCC. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Yale University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This phase II trial tests the combination of oleclumab and durvalumab in adults (and older teens in one cohort) with sarcoma that has recurred, is refractory, or has metastasized, including angiosarcoma, dedifferentiated liposarcoma, and osteosarcoma. It aims to learn how well the treatment works by measuring tumor shrinkage at 4 months and by estimating event-free survival for osteosarcoma patients, with additional safety and survival data collected. The study will also collect biomarker and immune-system data to understand how the therapy affects tumors and immune cells. Key exclusions include prior anti-PD-1/PD-L1 or anti-CD73 therapy, active autoimmune disease, untreated CNS metastases, recent anticancer therapy, and other conditions that could interfere with participation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer is being studied. Conditions: Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenocarcinoma, Stage IA Pancreatic Cancer AJCC v8 +3 • Eligibility: Inclusion Criteria: * Capable of giving written informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.…. Goal: This phase II trial studies the effects of gemcitabine, nab-paclitaxel, durvalumab, and oleclumab in treating patients with primary pancreatic cancer that may be able to be removed by surgery (resectable/borderline resectable). Chemotherapy drugs, such as gemcitabine and nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma is being studied. Conditions: Metastatic Alveolar Soft Part Sarcoma, Unresectable Alveolar Soft Part Sarcoma • Eligibility: Inclusion Criteria: * Patients must have histologically or cytologically confirmed alveolar soft part sarcoma that is not curable by surgery. Diagnosis of malignancy must be confirmed by the…. Goal: This phase II trial studies how well atezolizumab or atezolizumab plus bevacizumab works in treating patients with alveolar soft part sarcoma that has not been treated, has spread from where it started to other places in the body (advanced) and cannot be removed by surgery (unresectable). Atezolizumab works by unblocking the immune system, allowing the immune system cells to recognize and then attack tumor cells. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors is being studied. Conditions: Advanced Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma +23 • Eligibility: Inclusion Criteria: * Patients must have histologically confirmed, metastatic or unresectable malignancy of the following types: (a) non-small cell lung cancer (NSCLC), (b) triple-negative breast cancer (TNBC; defined…. Goal: This phase II trial studies cediranib maleate in combination with olaparib in treating patients with solid tumors that have spread to other parts of the body (advanced/metastatic) or cannot be removed by surgery (unresectable), including breast cancer, non-small cell lung cancer, small cell lung cancer, and pancreatic cancer. Cediranib maleate and olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests two regimens for metastatic renal cell cancer that has progressed after a PD-1/PD-L1 inhibitor: lenvatinib with everolimus versus cabozantinib alone. It aims to learn which treatment works better, how safe it is, and its impact on quality of life and overall survival. Participants are adults with 1–2 prior systemic therapies for metastatic RCC and measurable disease, randomized to one of the two options. Exclusions include prior use of any of the study drugs (lenvatinib, cabozantinib, or everolimus) and certain health conditions, such as uncontrolled hypertension, active infections, untreated brain metastases, or pregnancy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests whether adding the antidepressant fluoxetine to immunotherapy improves outcomes for people with advanced liver and gallbladder cancers. It is for adults 18 to 80 who have liver cancer or bile duct cancer that has spread or is locally advanced and who are about to start PD-1/PD-L1 inhibitor therapy, and who have depression or anxiety. The researchers want to learn if fluoxetine can better control the cancer, extend survival, and also improve mood and quality of life. Exclusions include active hepatitis B or C infection, a history of serious mental illness, fluoxetine allergy, or inability to take oral medications.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is a phase I trial testing the safety and best dose of combining hypofractionated radiation therapy with bintrafusp alfa for advanced intrahepatic cholangiocarcinoma (bile duct cancer that has spread). The goal is to find a safe radiation dose and see if the combination can help control the cancer while identifying side effects. Eligible participants are adults with confirmed intrahepatic cholangiocarcinoma who have at least two measurable tumors (one to radiate and one accessible for biopsy) and who have had or refused standard chemotherapy. Researchers will look at response rates, progression-free and overall survival, and how biomarkers related to TGF-beta and the immune system relate to outcomes. Key exclusions include pregnancy, uncontrolled illness, active autoimmune disease, prior immune checkpoint inhibitors, recent cancer treatment, and untreated CNS metastases.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Predictive Biomarkers for PD-1 Inhibitor Response in Squamous Cell Carcinoma is being studied. Conditions: Esophageal Squamous Cell Carcinoma (ESCC), Cervical Squamous Cell Carcinoma, Lung Squamous Cell Carcinoma +1 • Eligibility: Inclusion Criteria: 1. Patients with pathologically confirmed esophageal squamous cell carcinoma (ESCC), head and neck squamous cell carcinoma (HNSCC), cervical squamous cell carcinoma (CSCC), or lung squamous cell…. Goal: This study is a multicenter cohort investigation integrating both retrospective and prospective components, designed to evaluate the predictive performance of combined blood ELISA testing and tissue multiplex immunofluorescence (mIF) staining for assessing treatment response to PD-1 inhibitors in patients with squamous cell carcinoma. The retrospective cohort will analyze clinical data and pretreatment specimens (tissue biopsies and blood samples) from SCC patients who received PD-1 inhibitor therapy between April 2022 and June 2025 across participating centers. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Cancer Institute and Hospital, Chinese Academy of Medical Sciences.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) is being studied. Conditions: Uterine Cervical Neoplasms, Endometrial Neoplasms, Squamous Cell Carcinoma of Head and Neck +8 • Eligibility: Inclusion Criteria: * One of the following histologically or cytologically confirmed, advanced (unresectable or metastatic) solid tumors: * Squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix…. Goal: The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of pembrolizumab/vibostolimab co-formulation (MK-7684A) with or without other anticancer therapies in participants with selected advanced solid tumors. The primary hypothesis is that pembrolizumab/vibostolimab co-formulation is superior to pembrolizumab alone in terms of objective response rate or progression-free survival in participants with cervical cancer. Phase/Status/Sponsor: Unknown phase; COMPLETED; Merck Sharp & Dohme LLC.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC is being studied. Conditions: Extensive Stage Small Cell Lung Cancer • Eligibility: Inclusion Criteria: Voluntary participation in clinical studies. Male or female aged ≥ 18 years at the time of signing the ICF. Histologically or cytologically diagnosed with ES-SCLC (according…. Goal: This is a randomized, open-label study of Serplulimab plus chemotherapy (Carboplatin-Etoposide) in comparison with Atezolizumab plus chemotherapy in previously untreated US patients with ES-SCLC. Subjects in this study will be randomized to arm A or B at 1:1 ratio as follows: * Arm A (Serplulimab): Serplulimab + chemotherapy (carboplatin-etoposide) * Arm B (control): Atezolizumab + chemotherapy (carboplatin-etoposide) Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Shanghai Henlius Biotech.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer is being studied. Conditions: Breast Cancer • Eligibility: Inclusion Criteria: * Patients must have histologically and/or cytologically confirmed diagnosis of breast cancer, that is advanced/metastatic or unresectable, for which no curative therapy exists, and be negative…. Goal: The purpose of this study is to find out the effect that CFI-400945 and durvalumab have on breast cancer. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Canadian Cancer Trials Group.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Radiation Therapy in Combination With Durvalumab for People With Pancreatic Cancer is being studied. Conditions: Pancreatic Adenocarcinoma • Eligibility: Inclusion Criteria: * Patients with histopathologic or cytologic diagnosis of adenocarcinoma of the pancreas (PDAC), or suspicious for malignancy per pathology, which is deemed BR or LA PDAC…. Goal: The purpose of this study is to find out if combining durvalumab with standard stereotactic ablative radiotherapy (SABR) is an effective treatment for people with locally advanced or borderline resectable pancreatic cancer. The researchers will also look at the safety of the combination treatment and any side effects it causes. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Memorial Sloan Kettering Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The trial tests a combination therapy with Sacituzumab Tirumotecan for adults with unresectable locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma. - It has two groups: Cohort 1 patients who have not yet had systemic anti-cancer therapy, and Cohort 2 patients who progressed after first-line therapy or after chemo-immunotherapy. - The study aims to learn whether the combination can shrink tumors and improve outcomes while assessing safety and tolerability. - There are cohort-specific exclusions (e.g., prior immune checkpoint inhibitors for Cohort 1 and prior anti-angiogenic therapy or high bleeding risk for Cohort 2) plus general exclusions such as HIV, active infections, autoimmune disease, or pregnancy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is a Phase II, open-label, single-arm study testing AK104 (Cadonilimab) as a monotherapy for adults with recurrent or metastatic high-grade neuroendocrine carcinoma of the cervix who have already received prior treatment. It aims to estimate progression-free survival at 6 months and to assess response rates, duration of response, safety, and tolerability. The study also looks at whether HPV cell-free DNA in the blood could serve as a marker of response. Key exclusions include brain metastases, active infections, HIV or hepatitis B/C infection, autoimmune disease, and recent or prior immunotherapy or other anticancer treatments.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.